<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83711">
  <stage>Registered</stage>
  <submitdate>12/03/2009</submitdate>
  <approvaldate>28/05/2009</approvaldate>
  <actrnumber>ACTRN12609000375257</actrnumber>
  <trial_identification>
    <studytitle>The effect of dietary fibre and protein from lupin on blood glucose in type 2 diabetes</studytitle>
    <scientifictitle>The effect of dietary fibre and protein from lupin on blood glucose in type 2 diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>type 2 diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A study of the acute effects of dietary fibre and protein from legumes (when added to drinks) on blood glucose and insulin levels will be assessed.  Three treatments, administered in random order at least 1 week apart, will be compared  1) lupin flour high in protein and fibre [50 g of flour containing 22 g protein and 12.5 g fibre], plus 50 g glucose; 2) Soy protein [22 g] and fibre [12.5 g] provided as a mixture of isolated soy protein and concentrated soy fibre, plus 50 g glucose; 3) 50 g glucose (carbohydrate-matched control). Each treatment will be consumed as a 600 ml beverage, consumed over a 15 minute time period. Each treatment corresponds to a single clinic visit lasting 5 hours. Participants attend the clinic after a 12 hour overnight fast. A venous cannula will be inserted in the antecubital fossa vein and after a 15 minute rest baseline blood samples will be drawn. The treatment beverage is consumed, then blood samples are taken every 15 minutes for 1 hour, then every 30 minutes to 2 hours and then hourly to 4 hours.</interventions>
    <comparator>The total energy-matched control will be used to assess post-treatment effects of lupin or soy on appetite.

The carbohydrate-matched control will be used to assess post-treatment effects of lupin and soy on glucose and insulin responses.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma glucose concnetrations assessed using routine biochemical techniques performed in an accredited pathology laboratory</outcome>
      <timepoint>During the 4 hours post treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Plasma insulin concnetrations assessed using routine biochemical techniques performed in an accredited pathology laboratory</outcome>
      <timepoint>During the 4 hours post treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incretin hormones including glucagon-like peptide-1 (GLP-1) assessed using a commercially available assay</outcome>
      <timepoint>During the 4 hours post treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of type 2 diabetes within the previous 10 years (confirmed by a general practitioner, or evident at screening with fasting glucose &gt; 7 mmol/L); age 35-65 years; body mass index &lt; 40kg/m2; glycated haemoglobin &lt; 9%.</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Type 1 diabetes, insulin use, &gt;10% change in body weight in previous 6 months, smoking currently or within the last 6 months, daily alcohol consumption &gt;3 standard drinks for females and &gt;4 standard drinks for males, known allergy to lupin/nuts/soy/dairy/wheat/ gluten, other major chronic illness, change in regular medications in previous 3 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The order in which participants receive the treatments will be randomly assigned using computer generated random numbers. The sequence allocation will be sealed in opaque envelopes.</concealment>
    <sequence>Computer generated sequence of random numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>5/05/2009</anticipatedstartdate>
    <actualstartdate>5/05/2009</actualstartdate>
    <anticipatedenddate>30/06/2010</anticipatedenddate>
    <actualenddate>30/06/2010</actualenddate>
    <samplesize>33</samplesize>
    <actualsamplesize>29</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress>Stirling Hwy
Crawley
WA 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Department of Industry and Resources, State Government of Western Australia</fundingname>
      <fundingaddress>1 Adelaide Terrace
East Perth
Western Australia
6004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Dietary fibre and protein are thought to attenuate postprandial blood glucose levels.  This study in 33 participants with type 2 diabetes, will compare glucose and insulin responses following consumption of drinks containing glucose with and without protein and fibre from two different sources: lupin and soy. 

It is proposed that:
1. Fibre and protein-enriched drinks (lupin and soy) will be associated with lower postprandial levels of glucose and insulin compared with the carbohydrate-matched control; and
2. The lupin-enriched drink will be associated with lower levels of glucose and insulin compared with the soy-enriched drink.</summary>
    <trialwebsite />
    <publication>Dove ER, Mori TA, Chew GT, Barden AE, Woodman RJ, Puddey IB, Sipsas S, Hodgson JM. Lupin and soy reduce glycemia acutely in type 2 diabetes. Br J Nutr 2011; 106:1045-51</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Committee</ethicname>
      <ethicaddress>Wellington Street, Perth, WA 6000

GPO Box X2213
Perth, WA, 6001</ethicaddress>
      <ethicapprovaldate>4/05/2009</ethicapprovaldate>
      <hrec>2008/185</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Emma Dove</name>
      <address>School of Medicine &amp; Pharmacology
Medical Research Foundation Building
Level 3, Rear 50 Murray Street
PERTH Western Australia 6000</address>
      <phone>+61 8 9224 0341</phone>
      <fax />
      <email>Emma.Dove@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Emma Dove</name>
      <address>School of Medicine &amp; Pharmacology
Medical Research Foundation Building
Level 3, Rear 50 Murray Street
PERTH Western Australia 6000</address>
      <phone>+61 8 9224 0341</phone>
      <fax />
      <email>Emma.Dove@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jonathan Hodgson</name>
      <address>School of Medicine &amp; Pharmacology
Medical Research Foundation Building
Level 4, Rear 50 Murray Street
PERTH Western Australia 6000</address>
      <phone>+61 8 9224 0267</phone>
      <fax />
      <email>Jonathan.Hodgson@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Jonathan Hodgson</name>
      <address>GPO Box X2213 Perth WA 6847</address>
      <phone>61 8 9224 0267</phone>
      <fax />
      <email>jonathan.hodgson@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>